Financial reports
20-F
2023 FY
Annual report (foreign)
4 Apr 24
20-F
2022 FY
Annual report (foreign)
29 Mar 23
20-F
2021 FY
Annual report (foreign)
2 May 22
20-F
2020 FY
Annual report (foreign)
18 Mar 21
20-F
2019 FY
Annual report (foreign)
12 Mar 20
20-F
2018 FY
Annual report (foreign)
13 Mar 19
20-F
2017 FY
Annual report (foreign)
13 Mar 18
20-F/A
2016 FY
Annual report (foreign) (amended)
23 Jun 17
20-F/A
2015 FY
Annual report (foreign) (amended)
23 Jun 17
20-F
2016 FY
Annual report (foreign)
23 Mar 17
Current reports
6-K
Current report (foreign)
19 Mar 24
6-K
Current report (foreign)
15 Mar 24
6-K
Current report (foreign)
22 Nov 23
6-K
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
20 Nov 23
6-K
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
26 Sep 23
6-K
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
22 Sep 23
6-K/A
Current report (foreign) (amended)
21 Sep 23
6-K
Current report (foreign)
20 Sep 23
6-K
Current report (foreign)
13 Sep 23
6-K
Current report (foreign)
9 Aug 23
Registration and prospectus
POS AM
Prospectus update (post-effective amendment)
22 Nov 23
POS AM
Prospectus update (post-effective amendment)
1 Nov 23
424B4
Prospectus supplement with pricing info
18 Jul 23
F-1/A
Registration statement (foreign) (amended)
13 Jul 23
F-1/A
Registration statement (foreign) (amended)
12 Jul 23
FWP
Free writing prospectus
28 Jun 23
F-1/A
Registration statement (foreign) (amended)
28 Jun 23
F-1
Registration statement (foreign)
16 Jun 23
424B5
Prospectus supplement for primary offering
1 Jul 22
F-3
Shelf registration (foreign)
26 Mar 21
Proxies
No filings
Other
EFFECT
Notice of effectiveness
30 Nov 23
EFFECT
Notice of effectiveness
17 Jul 23
CORRESP
Correspondence with SEC
12 Jul 23
CORRESP
Correspondence with SEC
12 Jul 23
EFFECT
Notice of effectiveness
2 Apr 21
CORRESP
Correspondence with SEC
1 Apr 21
UPLOAD
Letter from SEC
31 Mar 21
CORRESP
Correspondence with SEC
2 Apr 18
EFFECT
Notice of effectiveness
2 Apr 18
UPLOAD
Letter from SEC
2 Apr 18
Ownership
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Baharaff Allen
12 Feb 24
SC 13G
CVI Investments, Inc.
21 Jul 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
Baharaff Allen
7 Feb 23
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 22
SC 13G/A
Baharaff Allen
11 Feb 22
SC 13G/A
Ibex Investors LLC
27 Jan 22
SC 13G
Nantahala Capital Management, LLC
16 Feb 21